# Ocera Therapeutics, Inc.

Ocera Therapeutics, Inc. is a company headquartered in Redwood City, CA, United States.

## Company overview

- **Legal name:** Ocera Therapeutics, Inc.
- **Former names in filing history:** TRANZYME INC (2003-12-29 to 2013-07-10)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Redwood City, CA, United States
- **Incorporated in:** CA
- **Fiscal year end:** December 31
- **SEC CIK:** 0001274644

## About

Ocera Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001274644, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2017-03-14, it reported annual revenue of USD 609,000; net income of USD -26,895,000; total assets of USD 29,639,000 for the fiscal period ended 2016-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2016 (period ended 2016-12-31)

- **Revenue:** $609,000 (USD 609,000)
- **Net income:** -$26.9M (USD -26,895,000)
- **Total assets:** $29.6M (USD 29,639,000)
- **Cash and equivalents:** $24.6M (USD 24,611,000)
- **Operating cash flow:** -$22.1M (USD -22,096,000)

### FY2015 (period ended 2015-12-31)

- **Revenue:** $133,000 (USD 133,000)
- **Net income:** -$26.5M (USD -26,522,000)
- **Total assets:** $44.7M (USD 44,737,000)
- **Cash and equivalents:** $35.9M (USD 35,921,000)
- **Operating cash flow:** -$20.6M (USD -20,614,000)

### FY2014 (period ended 2014-12-31)

- **Revenue:** $341,000 (USD 341,000)
- **Net income:** -$23.4M (USD -23,425,000)
- **Total assets:** $53.1M (USD 53,052,000)
- **Cash and equivalents:** $10.1M (USD 10,127,000)
- **Operating cash flow:** -$20.3M (USD -20,325,000)

### FY2013 (period ended 2013-12-31)

- **Revenue:** $85,000 (USD 85,000)
- **Net income:** -$17.5M (USD -17,514,000)
- **Total assets:** $51.8M (USD 51,820,000)
- **Cash and equivalents:** $15.5M (USD 15,533,000)
- **Operating cash flow:** -$12.0M (USD -11,994,000)

## Recent SEC filings

- Form 8-K — filed 2017-12-11 — period 2017-12-08 — 8-K
- Form 10-Q — filed 2017-11-14 — period 2017-09-30 — FORM 10-Q
- Form SC 13D — filed 2017-11-13 — SC 13D
- Form 8-K — filed 2017-11-02 — period 2017-11-01 — FORM 8-K
- Form 8-K — filed 2017-09-29 — period 2017-09-28 — 8-K - APPROVAL OF APPLICATION TO NASDAQ CAPITAL MARKET
- Form 8-K — filed 2017-08-04 — period 2017-08-03 — OCERA 8-K DELISTING NOTICE
- Form 10-Q — filed 2017-08-01 — period 2017-06-30 — 10-Q JUNE 30, 2017
- Form 8-K — filed 2017-08-01 — period 2017-08-01 — 8-K - EARNINGS RELEASE
- Form 8-K — filed 2017-06-22 — period 2017-06-20 — 8-K 2017 ANNUAL MEETING 062017
- Form 10-Q — filed 2017-05-09 — period 2017-03-31 — 10-Q
- Form 8-K — filed 2017-05-09 — period 2017-05-09 — 8-K
- Form DEF 14A — filed 2017-04-25 — period 2017-06-20 — DEF 14A

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/ocera-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology